[go: up one dir, main page]

PE20050346A1 - Glucopiranosiloxi-pirazoles como inhibidores del co-transportador de glucosa dependiente de sodio (sglt2) - Google Patents

Glucopiranosiloxi-pirazoles como inhibidores del co-transportador de glucosa dependiente de sodio (sglt2)

Info

Publication number
PE20050346A1
PE20050346A1 PE2004000813A PE2004000813A PE20050346A1 PE 20050346 A1 PE20050346 A1 PE 20050346A1 PE 2004000813 A PE2004000813 A PE 2004000813A PE 2004000813 A PE2004000813 A PE 2004000813A PE 20050346 A1 PE20050346 A1 PE 20050346A1
Authority
PE
Peru
Prior art keywords
alkyl
glucopyranosiloxy
methyl
substituted
sglt2
Prior art date
Application number
PE2004000813A
Other languages
English (en)
Inventor
Frank Himmelsbach
Peter Eickelmann
Leo Thomas
Edward Leon Barsoumian
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10339549A external-priority patent/DE10339549A1/de
Priority claimed from DE10359960A external-priority patent/DE10359960A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20050346A1 publication Critical patent/PE20050346A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE GLUCOPIRANOSILOXI-PIRAZOLES DE LA FORMULA I DONDE R1 ES ALQUINILO C3-C6, TETRAHIDROFURAN-3-ILO, TETRAHIDROPIRAN-3-ILO ENTRE OTROS; CON LA CONDICION DE QUE SI R3 (a) SE SELECCIONA DE UNO DE LOS SIGNIFICADOS DEL GRUPO A, O (b) SIGNIFIQUE, JUNTO CON R4, DIFLUOROMETILEN-DIOXI, O (c) SIGNIFIQUE CICLOALQUILO-(C3-C6)-OXI O CICLOALQUILIDEN-(C3-C6)-METILO Y, SIMULTANEAMENTE R4 SEA F, CL, BR, ALQUILO C1-C3, ALCOXI C1-C3 O METILO O METOXI SUSTITUIDO CON 1-3 F, ENTONCES R1 PUEDE SER TAMBIEN, H, ALQUILO C1-C6, ALQUILO C1-C4 SUSTITUIDO CON 1-3 F, ALQUILO C2-C4 SUSTITUIDO CON HIDROXI O ALCOXI C1-C3, ENTRE OTROS; R2 ES ALQUILO C1-C4 SUSTITUIDO O NO CON 1-4 F, O CICLOALQUILO C3-C6; R3 ES H, F, CL, BR, I, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS; R4 Y R5 SON H, F, CL, BR, ALQUILO C1-C3, ALCOXI C1-C3, ENTRE OTROS; R6, R7A, R7B Y R7C SON (ALQUIL(C1-C18))-CARBONILO, (ALQUIL(C1-C18))-OXICARBONILO, ARILCARBONILO, ENTRE OTROS; A ES TETRAHIDROFURAN3-IL-OXI, TETRAHIDROPIRAN-3-IL-OXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-(2-PROPIN-1-IL)-3-(ß-D-GLUCOPIRANOSILOXI)-4-(4-ETILBENCIL)-5-METIL-1H-PIRAZOL; 1-(2-PROPIN-1-IL)-3-(6-O-METOXICARBONIL-ß-D-GLUCOPIRANOSILOXI)-4-(4-ETILBENCIL)-5-METIL-1H-PIRAZOL; 1-((S)-TETRAHIDROFURAN-3-IL)-3-(ß-D-GLUCOPIRANOSILOXI)-4-(4-ETILBENCIL)-5-METIL-1H-PIRAZOL, ENTRE OTROS. LOS COMPUESTOS POSEEN ACTIVIDAD INHIBITORIA SOBRE EL CO-TRANSPORTADOR DE GLUCOSA DEPENDIENTE DE SODIO (SGLT2) UTIL EN EL TRATAMIENTO DE DIABETES
PE2004000813A 2003-08-26 2004-08-24 Glucopiranosiloxi-pirazoles como inhibidores del co-transportador de glucosa dependiente de sodio (sglt2) PE20050346A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10339549A DE10339549A1 (de) 2003-08-26 2003-08-26 Glucopyranosyloxy-Pyrazole, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10359960A DE10359960A1 (de) 2003-12-18 2003-12-18 Glucopyranosyloxy-pyrazole, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
PE20050346A1 true PE20050346A1 (es) 2005-06-15

Family

ID=34276522

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000813A PE20050346A1 (es) 2003-08-26 2004-08-24 Glucopiranosiloxi-pirazoles como inhibidores del co-transportador de glucosa dependiente de sodio (sglt2)

Country Status (11)

Country Link
EP (1) EP1660509B1 (es)
JP (1) JP4520988B2 (es)
AR (1) AR045490A1 (es)
AT (1) ATE422204T1 (es)
CA (1) CA2539032A1 (es)
DE (1) DE502004008951D1 (es)
ES (1) ES2322059T3 (es)
PE (1) PE20050346A1 (es)
TW (1) TW200526679A (es)
UY (1) UY28489A1 (es)
WO (1) WO2005021566A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
ES2385398T3 (es) * 2005-03-17 2012-07-24 Kissei Pharmaceutical Co., Ltd. Procedimiento para la producción de derivado de glucopiranosiloxipirazol
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
UY29694A1 (es) * 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CL2008000223A1 (es) * 2007-01-26 2008-05-23 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado glucopiranosiloxi-pirazol; y uso para el tratamiento de uno o mas trastornos neurodegenerativos.
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
NZ583369A (en) 2007-08-23 2011-08-26 Theracos Inc Benzylbenzene derivatives and methods of use
PE20091211A1 (es) 2007-11-30 2009-09-14 Boehringer Ingelheim Int Derivados de pirazolopirimidina como moduladores de pde9a
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010018438A2 (en) * 2008-08-11 2010-02-18 Hetero Research Foundation Tetrazole glycosides
PL2324002T3 (pl) 2008-08-22 2017-03-31 Theracos Sub, Llc Sposoby otrzymywania inhibitorów sglt2
CA2736304A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
PE20120017A1 (es) 2009-02-13 2012-02-12 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv, opcionalmente, un agente antidiabetico adicional, y sus usos
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
EA020798B1 (ru) 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
CA2775962C (en) 2009-09-30 2017-09-05 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
KR20120087950A (ko) 2009-10-20 2012-08-07 노파르티스 아게 글리코시드 유도체 및 그의 용도
PL2496583T3 (pl) 2009-11-02 2015-04-30 Pfizer Pochodne dioksabicyklo[3.2.1]oktano-2,3,4-triolowe
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
MX344770B (es) 2010-08-12 2017-01-06 Boehringer Ingelheim Int Gmbh * Derivados de 6-cicloalquil-1,5-dihidro-pirazolo (3,4-d) pirimidin-4-onas y su uso como inhibidores de pde9a.
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
CN103619862A (zh) 2011-04-14 2014-03-05 诺瓦提斯公司 糖苷衍生物及其用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
ES2740299T3 (es) 2013-03-14 2020-02-05 Msd Int Gmbh Métodos para preparar inhibidores de SGLT2
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
JP2016520564A (ja) 2013-04-18 2016-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
MX2019005435A (es) 2016-11-10 2019-07-10 Boehringer Ingelheim Int Composicion farmaceutica, metodos para tratamiento y sus usos.
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1145635C (zh) * 1999-08-31 2004-04-14 橘生药品工业株式会社 吡喃葡糖氧基吡唑衍生物、含该衍生物的药物组合物及其制备中的中间体
ES2337127T3 (es) * 2000-11-02 2010-04-21 Ajinomoto Co., Inc. Nuevos derivados de pirazol y remedios contra la diabetes que los contienen.
HU228915B1 (en) * 2000-12-28 2013-06-28 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof
WO2002068439A1 (fr) * 2001-02-26 2002-09-06 Kissei Pharmaceutical Co., Ltd. Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
WO2002068440A1 (en) * 2001-02-27 2002-09-06 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
JP4292570B2 (ja) * 2001-04-27 2009-07-08 味の素株式会社 Ｎ−置換ピラゾール−ｏ−グリコシド誘導体及びそれらを含有する糖尿病治療薬
JP4399251B2 (ja) * 2001-05-30 2010-01-13 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
JP4115105B2 (ja) * 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
WO2003020737A1 (en) * 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use

Also Published As

Publication number Publication date
JP4520988B2 (ja) 2010-08-11
ES2322059T3 (es) 2009-06-16
DE502004008951D1 (de) 2009-03-19
AR045490A1 (es) 2005-11-02
WO2005021566A2 (de) 2005-03-10
EP1660509A2 (de) 2006-05-31
UY28489A1 (es) 2005-03-31
EP1660509B1 (de) 2009-02-04
JP2007503413A (ja) 2007-02-22
ATE422204T1 (de) 2009-02-15
CA2539032A1 (en) 2005-03-10
WO2005021566A3 (de) 2005-04-07
TW200526679A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
PE20050346A1 (es) Glucopiranosiloxi-pirazoles como inhibidores del co-transportador de glucosa dependiente de sodio (sglt2)
PE20080927A1 (es) Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk)
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20020722A1 (es) Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20090888A1 (es) Compuestos heterociclicos como agentes moduladores del receptor acoplado a la proteina g gpr119
PE20091000A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
MA31419B1 (fr) Derives de pyridine
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20060297A1 (es) Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1
TNSN05320A1 (en) Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors
PE20050867A1 (es) DERIVADOS DE PIPERAZINA COMO INHIBIDORES DE LA INTERACCION DE gp 120 CON CD4
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
PE20070946A1 (es) COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
ES2328820T3 (es) Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
UY26391A1 (es) Inhibidores sglt2 de glucosidos de c-arilo y metodo
PE20161371A1 (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20020855A1 (es) Derivados de piperazina azaindoloxoacetico sustituidos con actividad antiviral
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
PE20090478A1 (es) Compuestos de indol macrociclicos como inhibidores de la proteasa del virus de la hepatitis c
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20081169A1 (es) Compuestos tipo pirazol y triazol sustituidos como inhibidores de ksp
PE20080207A1 (es) DERIVADOS DE 1-N-AMINO-2-IMIDAZOLIDINONAS COMO INHIBIDORES DEL CANAL DE POTASIO Kv1.5

Legal Events

Date Code Title Description
FD Application declared void or lapsed